Showing results (1-10 of 498) with videos related to
Sort By:
Pageof 50
Expert Review of Hematology|December 17, 2016
How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changesFulvio Massaro, Matteo Molica, Massimo BrecciaCurrent Cancer Drug Targets|October 4, 2017
Ponatinib: A Review of Efficacy and SafetyFulvio Massaro, Matteo Molica, Massimo BrecciaExpert Opinion on Pharmacotherapy|December 1, 2016
Second line small molecule therapy options for treating chronic myeloid leukemiaMatteo Molica, Fulvio Massaro, Massimo BrecciaInternational Journal of Hematologic Oncology|October 11, 2018
Current first- and second-line treatment options in acute promyelocytic leukemiaFulvio Massaro, Matteo Molica, Massimo BrecciaExpert Review of Molecular Diagnostics|September 21, 2017
Diagnostic and prognostic cytogenetics of chronic myeloid leukaemia: an updateMatteo Molica, Fulvio Massaro, Massimo BrecciaExpert Review of Hematology|March 10, 2018
Novel tyrosine-kinase inhibitors for the treatment of chronic myeloid leukemia: safety and efficacyFulvio Massaro, Gioia Colafigli, Matteo Molica, et al.Leukemia Research|July 22, 2016
Early molecular response in chronic myeloid leukemia and halving time: Latest evidencesMassimo Breccia, Matteo Molica, Gioia Colafigli, et al.Annals of Hematology|May 29, 2018
Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular eventsMatteo Molica, Emilia Scalzulli, Gioia Colafigli, et al.Leukemia Research|December 3, 2014
How tyrosine kinase inhibitors impair metabolism and endocrine system function: a systematic updated reviewMassimo Breccia, Matteo Molica, Giuliana AlimenaMediterranean Journal of Hematology and Infectious Diseases|September 21, 2020
Prognostic Significance of Transcript-Type BCR - ABL1 in Chronic Myeloid LeukemiaMatteo Molica, Elisabetta Abruzzese, Massimo BrecciaPageof 50